本文根据真实病例改编 [11]
参考资料:
[1]Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(4):638-45. doi: 10.1016/s0735-1097(01)01778-8
[2]Silbiger JJ. Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights. J Am Soc Echocardiogr. 2016;29(7):622-39. doi: 10.1016/j.echo.2016.03.003
[3]Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update.
JACC Heart Fail 2018;6:364-75.
[4]Syed U, Ching Companioni RA, Alkhawam H, et al. Amyloidosis of the gastrointestinal tract and the liver: clinical context, diagnosis and management. Eur J Gastroenterol Hepatol. 2016;28(10):1109-21. doi: 10.1097/MEG.0000000000000695
[5]Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-22.
[6]Cleveland Clinic Community Care. Lysosomal Storage Diseases. https://my.clevelandclinic.org/health/diseases/23383-lysosomal-storage-diseases
[7]Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med. 2011;13(6):563-8. doi: 10.1097/GIM.0b013e31820ad795
[8]Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267-77. doi: 10.1007/s00431-007-0635-4
[9]Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236-42. doi: 10.1111/j.1365-2362.2004.01309.x
[10]Martin WJ 2nd, Kachel DL, Vilen T, et al. Mechanism of phospholipidosis in amiodarone pulmonary toxicity. J Pharmacol Exp Ther. 1989;251(1):272-8.
[11]Pellikka PA, Dudzinski DM, Lubitz SA, et al. Case 10-2022: A 78-Year-Old Man with Marked Ventricular Wall Thickening. N Engl J Med. 2022;386(13):1266-1276. doi: 10.1056/NEJMcpc2201230
联系客服